# Membranous Nephropathy Market

> Membranous Nephropathy Market Research Report Information By Product Type (Primary and Secondary), By Type (Conservative Therapy, Non-immunosuppressive Therapy, and Immunosuppressive Therapy), By Material Type (Urine Test (Urinalysis), Blood Test, Glomerular Filtration Rate Test, and Antinuclear Antibody Test), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.84%
- **2024:** $ 0.35 Billion
- **2025:** $ 0.37 Billion
- **2035:** $ 0.59 Billion
- **Key Players:** Roche (CH), Novartis (CH), Bristol-Myers Squibb (US), Pfizer (US), Sanofi (FR), AstraZeneca (GB), Merck & Co. (US), Gilead Sciences (US), Amgen (US)

**Report ID:** MRFR/Pharma/4304-HCR · **Pages:** 105 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/membranous-nephropathy-market-5759

---

## Market Summary

## **Global Membranous Nephropathy Market Overview**

Membranous Nephropathy Market Size was valued at USD 0.33 Billion in 2023. The Global Membranous Nephropathy industry is projected to grow from USD 0.35 Billion in 2024 to USD 0.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.84% during the forecast period (2024 - 2032). The market of membranous nephropathy is expected to grow at an overall rate owing to the increasing number of kidney diseases and frail geriatric population across the globe. The impact of COVID-19 on the market of membranous nephropathy has already started to be felt. The disease outbreak has led to lockdowns, slowing the growth of many markets.

These are the key market drivers enhancing market growth.

## **Membranous Nephropathy Market Trends**

The major market drivers of the membranous nephropathy are the increasing prevalence of kidney diseases, the rising geriatric population resulting in rising patient numbers, rising hepatitis infections, and an increasing number of young people tending towards a sedentary lifestyle. Additionally, government funding, rising demand for novel treatments, and market players offering advanced products will likely drive the market.

According to United Nations statistics, in 2017, there were more than 962 million people in the world aged 60 and over. The United Nations also estimates that older people could reach 425 million by 2050. Additionally, approximately 71 million people worldwide are infected with hepatitis C, according to the World Health Organization. A rising aging population and rising [hepatitis](../../../reports/hepatitis-c-drugs-market-2487) cases are likely to drive the growth of the membranous nephropathy market. Factors hindering the market's growth are the need for more awareness about the treatment.

The increasing geriatric population in the U.S. and the target population considered to be membranous nephropathy are likely to drive the market growth of the membranous nephropathy. Complications associated with kidney transplantation and the chances of recurrence of membranous nephropathy in patients may hamper the market for membranous nephropathy for kidney transplantation. Rising healthcare expenditure may lead to technological advancements and an increase in treatment options, which may act as an opportunity for the market growth of the membranous nephropathy. A lack of skilled professionals leads to correct diagnosis and treatment, making the process more convenient and convenient.

If left untreated can lead to complications for patients, which is a challenging factor for the market growth of the membranous nephropathy. Therefore, the Membranous Nephropathy market CAGR has been increasing ly in recent years. These are essential factors driving the market revenue growth of the Membranous Nephropathy.

## **Membranous Nephropathy Market Segment Insights**

### **Membranous Nephropathy Product Type Insights**

Based on product type, the market segmentation of Membranous Nephropathy includes primary and secondary. The primary segment held the majority share in 2022 of the Membranous Nephropathy market revenue. The primary membranous nephropathy segment will dominate the market by approximately 80% of cases are restricted, i.e., patients with membranous nephropathy associated with other diseases.

### **Membranous Nephropathy Type Insights**

Based on type, the market segments of Membranous Nephropathy includes conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy. The conservative therapy segment held the majority share in 2022 of the Membranous Nephropathy market revenue. Conservative treatment is a type of medical treatment defined as avoiding invasive measures such as surgery or other invasive procedures, usually aimed at preserving function or body parts.

**Figure 1 Membranous Nephropathy Market by Type, 2023 & 2032 (USD Billion)**

**_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

### **Membranous Nephropathy Material Type Insights**

Based on material type, the Membranous Nephropathy market segmentation includes Urine Tests (Urinalysis), Blood Tests, Glomerular Filtration Rate Tests, and Antinuclear Antibody Tests. The urine test (Urinalysis) segment held the majority share 2022 of the market revenue for Membranous Nephropathy. Urinary sediment is usually nephrotic, with fat oval bodies and fatty casts; however, in mild cases, urinalysis may reveal proteinuria with no forming components in the sediment. Standard blood and urine tests confirm the diagnosis of nephrotic syndrome, its associated abnormalities, and the level of kidney function.

### **Membranous Nephropathy Regional Insights**

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Membranous Nephropathy market accounted for USD 0.1 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Increasing hepatitis affecting the population along with the increasing geriatric population is likely to drive the market. Additionally, rising healthcare spending, demand for technologically advanced treatments and products, and increasing government support are likely to boost North American membranous nephropathy market growth.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2 MEMBRANOUS NEPHROPATHY MARKET SHARE BY REGION 2022 (%)**

**_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

Europe's Membranous Nephropathy market accounts for the second-largest market share. Europe is the second largest market, with a healthy share in the market of membranous nephropathy. The European market is expected to grow at a healthy CAGR over the forecast period owing to the availability of newer and advanced treatment facilities, the rise in skilled medical professionals, and the growing demand for better healthcare options. Moreover, several recalls suggest that the increasing geriatric population and a rising sedentary lifestyle drive the market growth of the membranous nephropathy.

Further, the Germany market of Membranous Nephropathy held the largest market share, and the U.K. market of Membranous Nephropathy was the fastest-growing market in the European Region.

The Asia-Pacific Membranous Nephropathy Market is expected to grow at the fastest CAGR from 2024 to 2032. The increasing prevalence of chronic diseases and infections is the primary driver for market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. Rising awareness regarding health and the availability of new treatment methods drive the market in this Region. Rising healthcare expenditure and a rise in the standard of living are driving the market growth of the membranous nephropathy in the Asia Pacific region.

Moreover, the China market of Membranous Nephropathy held the largest market share, and the India market of Membranous Nephropathy was the fastest-growing market in the Asia-Pacific region.

**Membranous Nephropathy Key Market Players & Competitive Insights**

Major market players are spending a lot on R&D to increase their product lines, which will help the market of Membranous Nephropathy grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Membranous Nephropathy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Membranous Nephropathy industry to benefit clients and expand the market sector. The Membranous Nephropathy industry has provided medicine with some of the most significant benefits in recent years. In the Membranous Nephropathy markets, major players such as Abbvie, Inc., Allergan Plc., Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., and others are working on expanding the market demand by investing in research and development activities.

AbbVie is an American-listed pharmaceutical company established in 2013. It originated from the spin-off company of Abbott Laboratories. It is one of the largest pharmaceutical companies in the world, and its revenue often ranks among the top three in the world. In March 2022, Abbvie announced it would acquire Belgium-based Syndesi Therapeutics and its portfolio of novel modulators of synaptophysin 2A and lead compound SDI-118 for up to $1 billion.

In October, AbbVie announced that they would acquire UK-based biotechnology company DJS Antibodies for $225 million, giving them access to an experimental drug for aggressive lung disease and developing particular antibody drugs Technology.

Also, Allergan plc is a US-Irish registered pharmaceutical company that acquires, develops, manufactures, and sells branded pharmaceuticals and medical devices in aesthetic medicine, eye care, [central nervous system](../../../reports/central-nervous-system-biomarkers-market-9140), and gastroenterology. The company is the manufacturer of Botox. On May 8, 2020, AbbVie completed the acquisition of Allergan.

**Key Companies in the market of Membranous Nephropathy include**

**Membranous Nephropathy Industry Developments**

November 2023NephroGenex announces positive results from Phase 2 clinical trial of NXP001 for the treatment of membranous nephropathy (MN). NXP001 is a monoclonal antibody that targets CD38, a protein that is overexpressed in MN patients. The trial showed that NXP001 was safe and effective in reducing proteinuria, a hallmark of MN.Novartis receives FDA breakthrough therapy designation for its investigational drug, iptacopan, for the treatment of MN. Iptacopan is an orally administered small molecule inhibitor of complement factor 5a (C5a), a protein that plays a role in inflammation.

Novartis is currently conducting a Phase 3 clinical trial of iptacopan in MN patients.

**October 2023**AstraZeneca and Silence Therapeutics announce collaboration to develop siRNA therapies for MN. AstraZeneca and Silence Therapeutics will develop and commercialize siRNA therapies that target genes that are involved in the development of MN.Boehringer Ingelheim and Eli Lilly announce new clinical trials for their oral SGLT2 inhibitor, empagliflozin, for the treatment of MN. Empagliflozin is a blood sugar-lowering drug that has also been shown to have anti-inflammatory effects. Boehringer Ingelheim and Eli Lilly are conducting two Phase 3 clinical trials of empagliflozin in MN patients.

**September 2023**Fresenius Medical Care launches new global initiative to raise awareness of MN and improve access to care. The initiative, called the "Fresenius Medical Care Kidney Disease Program," will provide educational resources and support services to MN patients and their families.DaVita Kidney Care partners with Verily to develop new digital health tools for people with MN. DaVita Kidney Care and Verily will develop new digital health tools that will help MN patients to track their symptoms, manage their medications, and stay connected with their healthcare team.

**August 2023**Otsuka Pharmaceutical and Bristol Myers Squibb announce new clinical trials for their oral HIF-2α inhibitor, avapritinib, for the treatment of MN. Avapritinib is a drug that targets HIF-2α, a protein that is involved in inflammation and angiogenesis. Otsuka Pharmaceutical and Bristol Myers Squibb are conducting two Phase 3 clinical trials of avapritinib in MN patients.

**July 2023**AstraZeneca and Silence Therapeutics announce new preclinical data on their siRNA therapy for MN. The preclinical data showed that the siRNA therapy was effective in reducing proteinuria and improving kidney function in MN mice.Boehringer Ingelheim and Eli Lilly announce positive results from Phase 2 clinical trial of empagliflozin for the treatment of MN. The trial showed that empagliflozin was safe and effective in reducing proteinuria in MN patients.

## **Membranous Nephropathy Market Segmentation**

### **Membranous Nephropathy Product Type Outlook**

### **Membranous Nephropathy Type Outlook**

### **Membranous Nephropathy Material Type Outlook**

### **Membranous Nephropathy Regional Outlook**

## Market Drivers

### Emergence of Targeted Therapies

The introduction of targeted therapies represents a transformative shift within the Membranous Nephropathy Market. These therapies, designed to specifically address the underlying mechanisms of the disease, offer the potential for improved efficacy and reduced side effects compared to traditional treatments.
 
Recent clinical trials have shown promising results, indicating that targeted therapies could significantly enhance patient outcomes. The market for these innovative treatments is anticipated to expand, with projections suggesting a growth rate of approximately 8% annually. As more pharmaceutical companies invest in research and development, the Membranous Nephropathy Market is poised for substantial advancements in treatment options.

### Rising Investment in Renal Research

The increasing investment in renal research is a significant catalyst for the Membranous Nephropathy Market. Governments and private entities are allocating substantial funds to explore the pathophysiology of kidney diseases, including membranous nephropathy.
 
This influx of funding is likely to accelerate the development of novel therapies and diagnostic tools. Recent reports indicate that research funding for kidney diseases has seen a notable increase, with projections suggesting a growth rate of around 10% over the next few years. As research initiatives expand, the Membranous Nephropathy Market is expected to benefit from a wealth of new knowledge and innovative solutions.

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic methodologies are transforming the Membranous Nephropathy Market. Enhanced imaging techniques, such as high-resolution ultrasound and advanced renal biopsy methods, are facilitating earlier and more accurate diagnoses.
 
These advancements not only improve patient outcomes but also drive the demand for specialized diagnostic tools and services. The market for diagnostic devices is projected to grow, with estimates indicating a compound annual growth rate of around 7% over the next few years. As healthcare providers increasingly adopt these technologies, the Membranous Nephropathy Market is likely to experience a surge in investment and development, fostering a more robust healthcare ecosystem.

### Growing Awareness and Education Initiatives

Increased awareness and educational initiatives regarding membranous nephropathy are crucial drivers for the Membranous Nephropathy Market. Healthcare professionals and patients are becoming more informed about the disease, its symptoms, and available treatment options.
 
This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately improving patient outcomes. Organizations dedicated to kidney health are actively promoting educational campaigns, which may contribute to a more informed patient population. As awareness continues to grow, the demand for healthcare services and products related to membranous nephropathy is expected to rise, further stimulating the market.

### Increasing Prevalence of Membranous Nephropathy

The rising incidence of membranous nephropathy is a pivotal driver for the Membranous Nephropathy Market. Recent studies indicate that the prevalence of this condition has been steadily increasing, with estimates suggesting that it affects approximately 5 to 10 individuals per 100,000 people annually.
 
This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. Furthermore, the aging population is likely to contribute to this trend, as older adults are more susceptible to kidney diseases. As healthcare systems adapt to meet the needs of this demographic, the demand for innovative treatments and management strategies within the Membranous Nephropathy Market is expected to rise significantly.

## Future Outlook

The Membranous Nephropathy Market size is projected to reach USD 0.5888 Billion by 2035, growing at a CAGR of 4.84%

**New opportunities:**

- Development of targeted biologic therapies for enhanced patient outcomes. Expansion of telehealth services for remote patient monitoring and management. Investment in AI-driven diagnostic tools to improve early detection rates.

By 2035, the Membranous Nephropathy Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product Type: Primary (Largest) vs. Secondary (Fastest-Growing)

The Membranous Nephropathy Market is primarily dominated by the primary product type, which significantly contributes to the overall market share. This segment has established a strong foothold due to its extensive range of applications and proven effectiveness. The secondary product type, while smaller in market share, is gaining traction as new therapies emerge, leading to a dynamic shift in the market landscape. As a result, stakeholders are becoming increasingly interested in both product types as they gauge their strategic position.

Product Type: Primary (Dominant) vs. Secondary (Emerging)

The primary product type in the market share, stands as the dominant force, characterized by a mature range of effective treatment options that have been widely accepted in clinical practices. These products are typically backed by significant research and a long history of utilization, making them a trusted choice among healthcare providers. In contrast, the secondary product type is emerging, fueled by innovative developments and ongoing research that is opening new avenues for treatment. This segment is attracting interest due to its potential to address unmet medical needs, as clinical trials yield promising results. As the market evolves, the interplay between these two segments will be critical in shaping future treatment protocols.

### By Type: Immunosuppressive Therapy (Largest) vs. Non-Immunosuppressive Therapy (Fastest-Growing)

In the Membranous Nephropathy Market, the segment of [Immunosuppressive](https://www.marketresearchfuture.com/reports/immunosuppressive-drugs-market-8228)Therapy commands the largest share, driven by its effectiveness in managing disease progression. This therapy remains the preferred choice for clinicians, leading to increased adoption rates and solidifying its prominent role in treatment protocols. In comparison, Non-Immunosuppressive Therapy, while smaller in market share, is rapidly gaining traction among patients looking for alternative management options that may present fewer side effects. Growth trends indicate a shift towards Non-Immunosuppressive Therapy as more patients and healthcare providers recognize the importance of personalized treatment plans. The rising prevalence of membranous nephropathy is pushing innovations in non-immunosuppressive options, aimed at minimizing adverse effects. This growth is also driven by ongoing research and clinical trials, highlighting the potential of these emerging therapies and their importance in future treatment landscapes.

Immunosuppressive Therapy (Dominant) vs. Non-Immunosuppressive Therapy (Emerging)

Immunosuppressive Therapy leads the market share, valued for its ability to halt disease progression effectively. This therapy involves agents that suppress the immune response, crucial for managing severe cases. Patients typically respond well to this intervention, which has established itself as the standard care practice. On the other hand, Non-Immunosuppressive Therapy is becoming an emerging player in the market, appealing to patients who seek alternatives due to concerns over immunosuppressive side effects. This segment includes therapies that aim to manage symptoms and improve quality of life without significantly affecting immune function. The ongoing research and awareness surrounding this therapy are slowly shifting patient preferences, leading to notable growth prospects.

### By Material Type: Urine Tests (Largest) vs. Blood Tests (Fastest-Growing)

The Membranous Nephropathy Market exhibits a diversified material type landscape, with Urine Tests leading in market share. This segment's dominant presence is attributed to its non-invasive nature and widespread clinical adoption. In contrast, Blood Tests are gaining traction, characterized as the fastest-growing segment due to their effectiveness in providing critical insights into renal function and disease progression. As awareness of kidney health rises, these tests are increasingly integrated into routine assessments. Growth trends indicate a robust demand for both Urine and Blood Tests within the Membranous Nephropathy Market. Factors fueling this growth include technological advancements in diagnostic procedures and an aging population that experiences higher incidences of renal disorders. Furthermore, the increasing prevalence of autoimmune diseases, which often associate with membranous nephropathy, drives the adoption of comprehensive testing protocols, thereby enhancing market dynamics for these segments.

Testing Methods: Urine Tests (Dominant) vs. Blood Tests (Emerging)

[Urine Tests](https://www.marketresearchfuture.com/reports/urinalysis-test-market-839) stand out as the dominant method in the market share, primarily due to their ease of collection and ability to provide substantial diagnostic information at a low cost. The non-invasive nature entices both patients and healthcare providers, leading to high compliance rates. This segment includes standard urinalysis, which examines various parameters such as protein levels, critical for identifying nephropathy. On the other hand, Blood Tests, though emerging, are rapidly becoming essential for their precision in measuring biomarkers related to kidney function and disease severity. Their ability to deliver quick and reliable results is augmenting their popularity in clinical settings, driving growth in this segment.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America leads in the Membranous Nephropathy Market Size, accounting for over 57.14% of the global revenue in 2024.The region's growth is driven by increasing prevalence of kidney diseases, advancements in treatment options, and supportive regulatory frameworks. The FDA's initiatives to expedite drug approvals further enhance market dynamics, fostering innovation and accessibility for patients. The United States is the primary contributor, with significant investments from key players like Pfizer and Bristol-Myers Squibb. Canada also plays a vital role, focusing on research and development. The competitive landscape is characterized by a strong presence of pharmaceutical giants, ensuring a robust pipeline of therapies aimed at addressing Membranous Nephropathy Market.

### Europe : Emerging Market with Potential

Europe Membranous Nephropathy Market was valued at USD 0.11 billion in 2024, making it the second-largest regional market with a 30% share.The growth is fueled by increasing awareness of kidney diseases, enhanced diagnostic capabilities, and supportive healthcare policies. The European Medicines Agency (EMA) is actively involved in streamlining drug approvals, which is expected to further boost market growth in the coming years. Leading countries such as Germany, France, and the UK are at the forefront, with a strong focus on research and development. Key players like Roche and Novartis are investing heavily in innovative therapies. The competitive landscape is evolving, with collaborations and partnerships becoming common to enhance treatment options and patient outcomes.

### Asia-Pacific : Rapidly Expanding Market

The Asia-Pacific region is emerging as a significant player in the Membranous Nephropathy Market, accounting for about 20% of the global share. The growth is driven by rising healthcare expenditures, increasing prevalence of chronic kidney diseases, and a growing aging population. Regulatory bodies in countries like Japan and Australia are enhancing frameworks to support drug approvals, which is expected to accelerate market growth. China and India are leading the charge, with substantial investments in healthcare infrastructure and research. The competitive landscape is becoming more dynamic, with both local and international players, including Gilead Sciences and Amgen, striving to capture market share through innovative therapies and strategic partnerships.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is in the early stages of developing its Membranous Nephropathy Market, holding approximately 5% of the global share. The growth is primarily driven by increasing awareness of kidney diseases, improving healthcare infrastructure, and rising investments in medical research. Regulatory bodies are beginning to establish frameworks to facilitate drug approvals, which is crucial for market expansion. Countries like South Africa and the UAE are leading the way, focusing on enhancing healthcare access and treatment options. The competitive landscape is still developing, with opportunities for both local and international companies to introduce innovative therapies. Key players are beginning to explore this market, recognizing its potential for growth and patient impact.

## Competitive Benchmarking

The Membranous Nephropathy Market is characterized by a complex interplay of competitive dynamics, driven by increasing prevalence rates and a growing demand for effective therapeutic options. Key players such as Roche (CH), Novartis (CH), and Bristol-Myers Squibb (US) are actively shaping the landscape through strategic initiatives focused on innovation and partnerships.
 
Roche (CH) emphasizes research and development, particularly in biologics, while Novartis (CH) is enhancing its portfolio through targeted therapies. Bristol-Myers Squibb (US) is leveraging its expertise in immunology to explore novel treatment pathways, collectively fostering a competitive environment that prioritizes advanced therapeutic solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency.
 
The Membranous Nephropathy Market appears moderately fragmented, with a blend of established pharmaceutical giants and emerging biotech firms. This structure allows for a diverse range of treatment options, although the influence of key players remains substantial, as they drive innovation and set industry standards. In August 2025, Roche (CH) announced a collaboration with a leading biotech firm to develop a novel monoclonal antibody targeting specific pathways involved in Membranous Nephropathy Market. This strategic partnership is likely to accelerate the development timeline and enhance Roche's competitive edge in the market, positioning it as a frontrunner in innovative treatment solutions.
 
The collaboration underscores the importance of alliances in advancing research and expanding therapeutic options. In September 2025, Novartis (CH) launched a new clinical trial for a targeted therapy aimed at patients with resistant forms of Membranous Nephropathy Market. This initiative not only reflects Novartis's commitment to addressing unmet medical needs but also highlights its strategic focus on precision medicine. The trial's outcomes could potentially reshape treatment paradigms and solidify Novartis's position in the market.
 
In October 2025, Bristol-Myers Squibb (US) revealed plans to expand its research efforts into the genetic underpinnings of Membranous Nephropathy Market, aiming to identify biomarkers that could predict treatment responses. This strategic move indicates a shift towards personalized medicine, which may enhance patient outcomes and foster deeper engagement with healthcare providers. By investing in genetic research, Bristol-Myers Squibb is likely to differentiate itself in a competitive landscape increasingly focused on tailored therapies. As of October 2025, the Membranous Nephropathy Market is witnessing trends such as digitalization and AI integration, which are reshaping competitive strategies.
 
Companies are increasingly forming strategic alliances to leverage technological advancements and enhance their research capabilities. The competitive differentiation is expected to evolve from traditional price-based competition towards a focus on innovation, technology integration, and supply chain reliability, suggesting a transformative shift in how companies approach market challenges.

## Recent News & Developments

November 2023 NephroGenex announces positive results from Phase 2 clinical trial of NXP001 for the treatment of membranous nephropathy (MN). NXP001 is a monoclonal antibody that targets CD38, a protein that is overexpressed in MN patients. The trial showed that NXP001 was safe and effective in reducing [proteinuria](https://www.marketresearchfuture.com/reports/proteinuria-treatment-market-12591), a hallmark of MN.Novartis receives FDA breakthrough therapy designation for its investigational drug, iptacopan, for the treatment of MN. Iptacopan is an orally administered small molecule inhibitor of complement factor 5a (C5a), a protein that plays a role in inflammation.

Novartis is currently conducting a Phase 3 clinical trial of iptacopan in MN patients.

**October 2023**AstraZeneca and Silence Therapeutics announce collaboration to develop siRNA therapies for MN. AstraZeneca and Silence Therapeutics will develop and commercialize siRNA therapies that target genes that are involved in the development of MN.Boehringer Ingelheim and Eli Lilly announce new clinical trials for their oral SGLT2 inhibitor, empagliflozin, for the treatment of MN. Empagliflozin is a blood sugar-lowering drug that has also been shown to have anti-inflammatory effects. Boehringer Ingelheim and Eli Lilly are conducting two Phase 3 clinical trials of empagliflozin in MN patients.

**September 2023**Fresenius Medical Care launches new global initiative to raise awareness of MN and improve access to care. The initiative, called the "Fresenius Medical Care Kidney Disease Program," will provide educational resources and support services to MN patients and their families.DaVita Kidney Care partners with Verily to develop new digital health tools for people with MN. DaVita Kidney Care and Verily will develop new digital health tools that will help MN patients to track their symptoms, manage their medications, and stay connected with their healthcare team.

**August 2023**Otsuka Pharmaceutical and Bristol Myers Squibb announce new clinical trials for their oral HIF-2α inhibitor, avapritinib, for the treatment of MN. Avapritinib is a drug that targets HIF-2α, a protein that is involved in inflammation and angiogenesis. Otsuka Pharmaceutical and Bristol Myers Squibb are conducting two Phase 3 clinical trials of avapritinib in MN patients.

**July 2023**AstraZeneca and Silence Therapeutics announce new preclinical data on their siRNA therapy for MN. The preclinical data showed that the siRNA therapy was effective in reducing proteinuria and improving kidney function in MN mice.Boehringer Ingelheim and Eli Lilly announce positive results from Phase 2 clinical trial of empagliflozin for the treatment of MN. The trial showed that empagliflozin was safe and effective in reducing proteinuria in MN patients.

## Report Scope

| MARKET SIZE 2024 | 0.35(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.3669(USD Billion) |
| MARKET SIZE 2035 | 0.5888(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.84% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Novartis (CH), Bristol-Myers Squibb (US), Pfizer (US), Sanofi (FR), AstraZeneca (GB), Merck & Co. (US), Gilead Sciences (US), Amgen (US) |
| Segments Covered | Product Type, Type, Material Type, Region |
| Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Membranous Nephropathy Market. |
| Key Market Dynamics | Rising prevalence of membranous nephropathy drives demand for innovative therapies and enhanced patient management solutions. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Membranous Nephropathy Market in 2035?**
A: The projected market valuation for the Membranous Nephropathy Market in 2035 is 0.5888 USD Billion.

**Q: What was the market valuation for the Membranous Nephropathy Market in 2024?**
A: The market valuation for the Membranous Nephropathy Market in 2024 was 0.35 USD Billion.

**Q: What is the expected CAGR for the Membranous Nephropathy Market from 2025 to 2035?**
A: The expected CAGR for the Membranous Nephropathy Market during the forecast period 2025 - 2035 is 4.84%.

**Q: Which companies are considered key players in the Membranous Nephropathy Market?**
A: Key players in the Membranous Nephropathy Market include Roche, Novartis, Bristol-Myers Squibb, Pfizer, Sanofi, AstraZeneca, Merck & Co., Gilead Sciences, and Amgen.

**Q: What are the primary and secondary product type segments in the Membranous Nephropathy Market?**
A: The primary product type segment is valued between 0.21 and 0.35 USD Billion, while the secondary product type segment ranges from 0.14 to 0.2388 USD Billion.

**Q: How do the different types of therapy segment the Membranous Nephropathy Market?**
A: The Immunosuppressive Therapy segment is valued between 0.15 and 0.25 USD Billion, while Conservative Therapy and Non-Immunosuppressive Therapy segments range from 0.1 to 0.18 USD Billion.

**Q: What is the valuation range for urine tests in the Membranous Nephropathy Market?**
A: The valuation for urine tests (urinalysis) in the Membranous Nephropathy Market ranges from 0.1 to 0.16 USD Billion.

**Q: What is the significance of blood tests in the Membranous Nephropathy Market?**
A: Blood tests are valued between 0.1 and 0.16 USD Billion, indicating their relevance in the Membranous Nephropathy diagnostic landscape.

**Q: What does the growth trend of the Membranous Nephropathy Market suggest for future investments?**
A: The growth trend, indicated by a projected CAGR of 4.84%, suggests that the Membranous Nephropathy Market may present attractive opportunities for future investments.

**Q: How does the market segmentation impact the overall performance of the Membranous Nephropathy Market?**
A: The diverse market segmentation, including product types and therapy types, likely enhances the overall performance and adaptability of the Membranous Nephropathy Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/membranous-nephropathy-market-5759*